Lead Product(s) : 12-O-Tetradecanoylphorbol-13-acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : WeFunder
Deal Size : $5.0 million
Deal Type : Funding
PhorMed Inc Launches New Regulation CF Equity Crowdfunding Campaign on WeFunder
Details : Funding will support Phormed's RP-323 development, which may modulate malignant cell differentiation via multiple pathways, evaluated in patients with acute respiratory distress syndrome.
Product Name : RP-323
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 22, 2024
Lead Product(s) : 12-O-Tetradecanoylphorbol-13-acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : WeFunder
Deal Size : $5.0 million
Deal Type : Funding
Lead Product(s) : 12-O-Tetradecanoylphorbol-13-acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phormed Announces ARDS Study Results
Details : These studies have generated positive results showing RP-323 (12-O-tetradecanoylphorbol-13-acetate) significantly reduces the influx of inflammatory cells into the lungs thereby limiting damage to the lungs.
Product Name : RP-323
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2022
Lead Product(s) : 12-O-Tetradecanoylphorbol-13-acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable